Biotechnology industries

Pharmaceutical industry

Generex Biotechnology Corporation Presents at World Congress on Controversies in Obesity, Diabetes, and Hypertension

Generex Biotechnology Corporation, a leader in drug delivery for metabolic diseases, announced its participation in The World Congress on Controversies in Obesity, Diabetes, and Hypertension (CODHy) in Berlin, Germany. The company's executives will make several presentations, including a podium presentation by Dr. Gerald Bernstein on clinical studies related

Pharmaceutical industry

Inovio Biomedical Corporation Announces Breakthrough in DNA Vaccine Development for Hepatitis C

Inovio Biomedical Corporation, a leader in enabling the development of DNA vaccines using electroporation-based DNA delivery, announced that its partner, Tripep AB of Sweden, has demonstrated promising results in a murine model of hepatitis C. The study, conducted in collaboration with Inovio, showed that the proprietary DNA vaccine, ChronVac-C, administered

Pharmaceutical industry

Generex Biotechnology Presents at 2006 Canadian Diabetes Association Conference

Generex Biotechnology, a leading company in drug delivery for metabolic diseases, made a significant presentation at the 2006 Canadian Diabetes Association (CDA) Professional Conference and Annual Meetings in Toronto, Canada. The company highlighted its proprietary oral insulin spray product, Generex Oral-lyn, in a paper titled "3-Month Interim Results (6-Month

Pharmaceutical industry

Biotech Bidding War Ends with Genzyme's Acquisition of AnorMed

Genzyme Corp. declared victory in the first major bidding war in the biotechnology industry, acquiring AnorMed Inc. for $580 million, after a hostile bid from Cambridge rival Millennium Pharmaceuticals Inc. failed to materialize. Millennium had hoped to notch its first major deal by buying AnorMed, a Canadian firm developing an

Pharmaceutical industry

Cougar Biotechnology Announces Positive Phase I Data for Prostate Cancer Drug CB7630

Presented today at the National Cancer Research Institute (NCRI) Cancer Conference in Birmingham, UK, Cougar Biotechnology's prostate cancer drug CB7630 (abiraterone acetate) has demonstrated promising results in a Phase I trial. The data, presented by Dr. Johann S. deBono, shows that CB7630 was well-tolerated at high doses, with

Pharmaceutical industry

Codexis Achieves Development Milestone in Partnership with Schering-Plough

Codexis, Inc. has reached an important development milestone under a research agreement with Schering-Plough Corporation (SGP). The collaboration aims to rapidly generate a novel biocatalytic process for producing a key intermediate in an undisclosed human therapeutics compound. This project leverages Codexis' proprietary MolecularBreeding platform, which is expected to reduce

Pharmaceutical industry

Biotech Mergers and Acquisitions Spark Activity in Quiet Industry

A sudden wave of mergers and buyouts has sparked interest in the biotechnology industry, which is heavily reliant on deal-making to validate new ideas. Recent acquisitions, including Gilead Sciences' $2.5 billion purchase of Myogen Inc. and Millennium Pharmaceuticals' bid for AnorMed Inc., have highlighted the curious economics

Pharmaceutical industry

Anormed Board of Directors Rejects Genzyme's Unsolicited Acquisition Offer

Anormed, Inc. has announced that its board of directors, after careful consideration and consultation with financial and legal advisors, recommends that shareholders reject Genzyme Corp.'s unsolicited offer to acquire Anormed for $8.55 per share in cash. The board, led by Joseph Dougherty, chairman of the Strategic Initiatives

Pharmaceutical industry

Novel BiTE Molecule Shows Promise in Cancer Therapy

In a collaborative research effort between MedImmune, Inc. and Micromet, Inc., a novel BiTE molecule, bscEphA2xCD3, has been developed to target the tyrosine kinase receptor EphA2, which is frequently overexpressed on solid tumors. This innovative compound has shown significant potential in in vitro studies, killing tumor cells at low nanogram/

Pharmaceutical industry

Celator Pharmaceuticals Receives European Patent for CombiPlex Technology

Celator Pharmaceuticals, a biotechnology company dedicated to developing combination chemotherapies, has received confirmation that the European Patent Office intends to grant a European patent for its proprietary CombiPlex technology. This decision provides the company with broad protection for compositions and methods related to ratiometric administration of drug combinations that act

Pharmaceutical industry

Oncolytics Biotech Inc. Receives MHRA Approval for Phase II Clinical Trial of Reolysin Combination Therapy

Oncolytics Biotech Inc. (ONC, ONCY) has taken a crucial step forward in the development of its Reolysin-based cancer therapy, with the U.K. Medicines and Healthcare products Regulatory Agency (MHRA) granting approval for a Phase II clinical trial. The trial aims to evaluate the anti-tumor effects of intratumoral administration of

Pharmaceutical industry

Lpath, Inc. Breaks Ground in Cancer Research with Functional Antibodies Against LPA

Lpath, Inc., a theranostics company, has made a groundbreaking discovery in cancer research by generating functional antibodies against lysophosphatidic acid (LPA), a key bioactive lipid and potent cancer promoter. This achievement marks a significant milestone in the fight against cancer, as LPA has been recognized as a crucial contributor to